Our viral engineering platform, InViroMax, offers unlimited potential to create fully-customized delivery vehicles for oncology and non-oncology indications.
Engineering Next-Generation Viral Vectors
Despite the promise of gene therapy and cancer immunotherapies, current viral vectors face significant bottle-necks. From issues with limited carry capacity (AAV is limited to 4.6 kB), safety concerns, and lack of delivery capabilities beyond the liver, viral vectors lack the capacity for effective treatment. Leveraging the Nobel-prize winning technology of Directed Evolution, ReIGNITE is accelerating the development of viral vectors that can overcome biological barriers in gene therapy, paving the way for safer, more effective treatments for patients.
Starting with the indication first, we then select the virus, strain, and serotype to fit the specific needs of the patient.
We simultaneously introduce multiple modifications in a single step, enabling significant time savings for engineering new vectors.
We create diverse viral libraries and subject them to repeated selective pressures that can mimic the therapeutic enviornment. We then select variants that emerge with desired traits, such as mutations enhance cell-specific tropism, or mutations that improve IV delivery and intratumoral spread.
In addition to single or multiple therapeutic transgenes, adding on/off switches and imaging capabilities enables the precise control and real-time monitoring of our therapies.
Our systemically delivered viral vectors enhance patient outcomes by effectively treating widespread disease. This approach improves therapeutic reach, minimizes invasive procedures, and increases overall treatment efficacy.
ReIGNITE's high-throughput viral vector discovery platform uses directed evolution to create proprietary oncolytic immunotherapeutics and gene therapies.
Our vectors are designed to deliver large payloads of genetic material and gene editing constructs, with a capacity of up to 50 kB.
Our vectors are engineered to include tissue-specific promoters, enabling endogenous regulation.
Our viruses are engineered for efficient IV delivery targeting solid tumors, metastatic cancer, and monogenic genetic diseases.
Our modular InViroMax platform enables the precise engineering of vectors that are fit for purpose, depending on the target indication.
Our vectors includes non-invasive imaging capabilities & off-switches for added safety.
Our engineered viruses contain stable dsDNA genomes, ensuring consistent transgene expression
Directed Evolution in Action
We offer a solution to the challenges facing millions of patients worldwide
ReIGNITE's lead program (RIG-1250) is an oncolytic immunotherapy employing an engineered vaccinia virus, administered intravenously, to target solid tumors. Vaccinia does not have a specific receptor for cell entry allowing it to infect a wide range of cells with a natural tropism to cancer cells.
ReIGNITE is developing novel high-capacity adenovirus vectors, offering a transgene carry capacity of ~36 kB. This larger carrying capacity facilitates the delivery of larger transgenes, gene editing tools, multiple genes, and essential regulatory elements, unlocking new possibilities in gene therapy.
RelGNITE is also expanding and diversifying its pipeline of therapeutics across hematologic malignancies, solid tumors, and monogenic genetic diseases that require the delivery of large or multiple transgenes. Explore our pipeline so see what we are working on
